DC-159a Shows Inhibitory Activity against DNA Gyrases of Mycobacterium leprae.
BACKGROUND
Fluoroquinolones are a class of antibacterial agents used for leprosy treatment. Some new fluoroquinolones have been attracting interest due to their remarkable potency that is reportedly better than that of ofloxacin, the fluoroquinolone currently recommended for treatment of leprosy. For example, DC-159a, a recently developed 8-methoxy fluoroquinolone, has been found to be highly potent against various bacterial species. Nonetheless, the efficacy of DC-159a against Mycobacterium leprae is yet to be examined.


RESULTS
To gather data that can support highly effective fluoroquinolones as candidates for new remedies for leprosy treatment, we conducted in vitro assays to assess and compare the inhibitory activities of DC-159a and two fluoroquinolones that are already known to be more effective against M. leprae than ofloxacin. The fluoroquinolone-inhibited DNA supercoiling assay using recombinant DNA gyrases of wild type and ofloxacin-resistant M. leprae revealed that inhibitory activities of DC-159a and sitafloxacin were at most 9.8- and 11.9-fold higher than moxifloxacin. Also the fluoroquinolone-mediated cleavage assay showed that potencies of those drugs were at most 13.5- and 9.8-fold higher than moxifloxacin. In addition, these two drugs retained their inhibitory activities even against DNA gyrases of ofloxacin-resistant M. leprae.


CONCLUSIONS
The results indicated that DC-159a and sitafloxacin are more effective against wild type and mutant M. leprae DNA gyrases than moxifloxacin, suggesting that these antibacterial drugs can be good candidates that may supersede current fluoroquinolone remedies. DC-159a in particular is very promising because it is classified in a subgroup of fluoroquinolones that is known to be less likely to cause adverse effects. Our results implied that DC-159a is well worth further investigation to ascertain its in vivo effectiveness and clinical safety for humans.
Division of Bioresources, Hokkaido University Research Center for Zoonosis Control, Sapporo, Japan.
Tomoyuki
T
Yamaguchi
Central Research Laboratory, Kissei Pharmaceutical Co., Ltd, Azumino, Japan.
Kazumasa
K
Yokoyama
Division of Bioresources, Hokkaido University Research Center for Zoonosis Control, Sapporo, Japan.|Global Station for Zoonosis Control, Global Institution for Collaborative Research and Education (GI-CoRE), Hokkaido University, Sapporo, Japan.
Chie
C
Nakajima
Division of Bioresources, Hokkaido University Research Center for Zoonosis Control, Sapporo, Japan.|Global Station for Zoonosis Control, Global Institution for Collaborative Research and Education (GI-CoRE), Hokkaido University, Sapporo, Japan.
Yasuhiko
http://orcid.org/0000-0002-1313-1494
Y
Suzuki
Lepr Rev. 2007 Dec;78(4):343-52
18309708
Antimicrob Agents Chemother. 2000 Oct;44(10 ):2919-21
10991891
Lepr Rev. 2010 Jun;81(2):137
20825118
Lepr Rev. 2012 Sep;83(3):269-81
23356028
Antimicrob Agents Chemother. 2008 Sep;52(9):3113-7
18573938
Int J Antimicrob Agents. 2003 Mar;21(3):251-5
12636987
PLoS Negl Trop Dis. 2012;6(10):e1838
23071850
Antimicrob Agents Chemother. 2012 Feb;56(2):697-702
22106221
Annu Rev Biochem. 2001;70:369-413
11395412
Antimicrob Agents Chemother. 1993 Oct;37(10):2217-23
8257147
Drugs. 1999;58 Suppl 2:29-36
10553702
Wkly Epidemiol Rec. 2014 Sep 5;89(36):389-400
25202781
J Clin Microbiol. 2012 Jun;50(6):1912-7
22495562
Antimicrob Agents Chemother. 2008 Feb;52(2):745-7
18070975
Toxicol Sci. 2000 Aug;56(2):290-6
10910986
J Antimicrob Chemother. 1999 May;43 Suppl B:77-82
10382879
Antimicrob Agents Chemother. 2010 Jun;54(6):2684-6
20368403
Clin Infect Dis. 2005 Jul 15;41 Suppl 2:S144-57
15942881
Antimicrob Agents Chemother. 2008 Jan;52(1):65-76
17938194
Br J Dermatol. 2003 Dec;149(6):1232-41
14674902
Indian J Dermatol Venereol Leprol. 2009 Mar-Apr;75(2):126-35
19293498
Antimicrob Agents Chemother. 2008 Oct;52(10):3763-75
18573936
Antimicrob Agents Chemother. 2004 Apr;48(4):1281-8
15047530
Antimicrob Agents Chemother. 2007 May;51(5):1643-8
17325221
Jpn J Antibiot. 2011 Oct;64(5):319-37
22428215
J Infect. 2005 Jan;50(1):6-11
15603834
Clin Infect Dis. 1999 Feb;28(2):352-64
10064255
Methods Mol Med. 2008;142:11-23
18437302
Antimicrob Agents Chemother. 2006 Jan;50(1):104-12
16377674
J Antimicrob Chemother. 2001 Jul;48 Suppl 1:5-16
11420333
N Engl J Med. 1991 Feb 7;324(6):384-94
1987461
Lancet Infect Dis. 2011 Jun;11(6):464-70
21616456
Antimicrob Agents Chemother. 2011 Aug;55(8):3661-7
21646485
J Infect Chemother. 2013 Jun;19(3):486-94
23525983
J Infect Chemother. 2003 Mar;9(1):12-5
12673400
J Antimicrob Chemother. 2003 May;51 Suppl 1:21-7
12702700
Lepr Rev. 2009 Jun;80(2):205-9
19743625
J Antimicrob Chemother. 2003 May;51(5):1109-17
12697644
Antimicrob Agents Chemother. 2004 Mar;48(3):799-803
14982767
J Infect Chemother. 2003 Dec;9(4):292-6
14691648